Johnson & Johnson Reports Q4 and Full-Year 2025 Results
Summary
Johnson & Johnson announced its Q4 and full-year 2025 results on January 21, 2026, via Exhibit 99.1 press release. For Q4 2025, reported sales grew 9.1% to $24.6 billion, with EPS of $2.10 and adjusted EPS of $2.46. Full-year 2025 reported sales increased 6.0% to $94.2 billion, with EPS of $11.03 and adjusted EPS of $10.79. Both Q4 and full-year EPS figures include a $(0.10) impact from the Halda Therapeutics acquisition. * Significant innovation included approvals for CAPLYTA, RYBREVANT FASPRO, and LAZCLUZE. * Landmark data was reported for TECVAYLI plus DARZALEX FASPRO. * The company acquired Halda Therapeutics and submitted the OTTAVA Robotic Surgical System.
Why It Matters
Investors should note the reported sales growth of 9.1% for Q4 2025 and 6.0% for the full year, alongside EPS figures, as these indicate the company's financial performance and operational health. Strategic developments like new drug approvals and the Halda Therapeutics acquisition signal future growth potential.
These filing summaries are free and always will be. If this helped you spot material events, consider supporting us.
Want to see how JNJ traded around this filing?
Check real-time charts and technical analysis on TradingView to see market reaction to this event.
View JNJ Charts on TradingViewAffiliate link
Is this filing part of a pattern?
One disclosure is noise. Get a structured briefing covering 12 months of SEC filings, disclosure signals, and what to watch next.
Key Quote
“On January 21, 2026, Johnson & Johnson (the "Company") issued the attached press release (Exhibit 99.1) announcing its sales and earnings for the fourth quarter and full year ended December 28, 2025.”
— From Item 2.02
Filing Details
Reported Items
Additional Information
- CIK Number
- 0000200406
- Filing Date
- Wednesday, January 21, 2026
- Filing Time
- 12:00 AM UTC
- Form Type
- 8-K
- Materiality Level
- high
- Sentiment
- positive